Working... Menu

Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer (LAPTEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00614978
Recruitment Status : Completed
First Posted : February 14, 2008
Last Update Posted : September 19, 2012
Information provided by (Responsible Party):
Jules Bordet Institute

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2011
  Actual Study Completion Date : June 2011